文献速递慢性静脉疾病

激光冷冻硬化疗法与传统硬化疗法治疗网状静脉和毛细血管扩张的随机对照试验

Laser cryo-sclerotherapy versus conventional sclerotherapy for reticular veins and telangiectasias: A randomized controlled trial.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-09-15

单中心前瞻性随机对照试验纳入56例CEAP C1女性患者,比较激光冷冻硬化疗法(LCS)与联合传统硬化疗法(CS)的美学效果。LCS组在所有GAIS结局上优于CS组,效应量为中等至较大,且瘀斑持续时间更短;但LCS成本与复杂度更高。

要点

  • LCS在D1→D90无AR、D1→D90有AR、D30→D90无AR及有AR的GAIS比较中均优于CS,效应量中等至较大。
  • LCS组80.0%患者在D30至D90继续改善,CS组仅29.1%,且CS组出现8.3%的D90严重色素沉着。
  • LCS瘀斑持续时间更短(中位5.0天 vs 10.0天),无深静脉血栓或溃疡发生。

核心结论

  • LCS方案在所有GAIS结局上优于CS,效应量中等至较大,且评估者间一致性良好。
  • LCS的美学反应呈渐进性,在D30至D90巩固,后期效应量最大,AR可放大检测效应并提高评估者间一致性。

研究设计与样本

  • 单中心前瞻性随机对照试验,评估60例,56例CEAP C1女性患者随机分组,仅治疗一条下肢。
  • LCS组32例(Nd:YAG 1064 nm + 75%高渗葡萄糖),CS组24例(67.5%葡萄糖 + 0.3%聚多卡醇)。
  • LCS组2例在D1至D30失访,54例(LCS组30例、CS组24例)完成90天随访并按方案分析。

主要发现

  • LCS组在D1→D90无AR的GAIS比较中优于CS组(P = .026;r = 0.34;95%CI 0.04-0.58;中等效应)。
  • LCS组在D1→D90有AR(P < .001;r = 0.53;95%CI 0.28-0.72)、D30→D90无AR(P < .001;r = 0.56;95%CI 0.31-0.74)及有AR(P < .001;r = 0.52;95%CI 0.26-0.71)的比较中均优于CS组。
  • Bonferroni校正后(α = .0125),仅D1→D90无AR比较未达显著性,其余三项仍显著。
  • LCS组80.0%患者在D30至D90继续改善,CS组为29.1%(70.8%无变化)。
  • LCS组瘀斑持续时间显著短于CS组(中位5.0天 vs 10.0天;P = .012);D90严重色素沉着仅见于CS组(8.3% vs 0%;P = .019;r = 0.22;小效应;把握度36.4%;探索性发现)。

关键数值与推荐

  • GAIS评估者间一致性:κ = 0.735-0.913(显著至近乎完美);并发症分级κ = 1.000(完美)。
  • 两组Aberdeen静脉曲张问卷评分均显著改善(P < .001),组间无差异。
  • 无深静脉血栓或溃疡病例发生。

临床怎么用

  • 对于CEAP C1网状静脉和毛细血管扩张患者,LCS可提供更优且渐进的美学改善,尤其D30至D90持续改善。
  • AR(VeinViewer Flex)可作为标准化工具用于美学静脉学随机对照试验,放大效应并提高评估一致性。
  • 临床选择需权衡LCS更高的成本与复杂度相对于CS的优势。

局限性

  • D90严重色素沉着的比较为探索性发现,把握度仅36.4%。
  • 研究仅纳入女性、Fitzpatrick I-III型且CEAP C1患者,结果外推受限。
  • 样本量较小(56例随机,54例分析),随访90天,长期效果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether the hybrid laser cryo-sclerotherapy (LCS; Nd:Y-AG 1064 nm + 75% hypertonic glucose [HG]) protocol produces superior aesthetic outcomes compared with combined conventional sclerotherapy (CS: 67.5% glucose + 0.3% polidocanol [POL]) for the treatment of lower limb reticular veins and telangiectasias (CEAP C1). METHODS: For this single-center, prospective randomized controlled trial, 60 patients were assessed for eligibility; 4 did not provide informed consent and were not randomized. A total of 56 female patients with CEAP C1 disease and Fitzpatrick phototypes I-III were randomized, with only one lower limb treated per participant: 32 to the LCS group (Nd:YAG 1064 nm + HG75%) and 24 to the CS group (HG67.5% + POL0.3%). Two participants who underwent LCS were subsequently lost to follow-up between Day 1 and Day 30; 54 participants (30 and 24 from the LCS and CS groups, respectively) completed the 90-day follow-up and were analyzed per protocol. Standardized photographs were obtained on Day 1, Day 30, and Day 90, with and without augmented reality (AR; VeinViewer Flex), and were assessed by two blinded external vascular physicians using the Global Aesthetic Improvement Scale (GAIS). Complications, residual pigmentation, and quality of life (Aberdeen Varicose Vein Questionnaire) were evaluated as secondary end points. RESULTS: Both groups had equivalent baseline characteristics. The LCS group was superior to the CS group in all GAIS outcomes: D1→D90 without AR (P = .026; r = 0.34; 95% confidence interval [CI], 0.04-0.58; moderate effect); D1→D90 with AR (P < .001; r = 0.53; 95% CI, 0.28-0.72; large effect); D30→D90 without AR (P < .001; r = 0.56; 95% CI, 0.31-0.74; large effect); D30→D90 with AR (P < .001; r = 0.52; 95% CI, 0.26-0.71; large effect). After Bonferroni correction for these four primary comparisons (α = .0125), the D1→D90 comparison without AR no longer reached significance, whereas the remaining three comparisons did. Temporal analysis revealed a progressive late aesthetic response in the LCS group; 80.0% of participants continued improving between Day 30 and Day 90 vs 29.1% in the CS group (70.8% with No Change). The ecchymosis duration was significantly shorter in the LCS group (median, 5.0 vs 10.0 days; P = .012). Severe pigmentation on Day 90 was observed exclusively in the CS group (8.3% vs 0%; P = .019; r = 0.22; small effect; power = 36.4%; this finding is exploratory, see the Discussion section). No cases of deep vein thrombosis or ulcer occurred. Aberdeen Varicose Vein Questionnaire score improvement was significant in both groups (P < .001), with no intergroup difference. Inter-rater agreement was substantial to near-perfect for GAIS assessments (κ = 0.735-0.913) and perfect for complication grading (κ = 1.000). CONCLUSIONS: The LCS protocol was superior to CS in all GAIS outcomes, with moderate-to-large effect sizes and consistent inter-rater agreement. The aesthetic response was progressive, consolidating between Day 30 and Day 90, with the largest effect size in the late period. AR amplified the magnitude of the detected effects and improved inter-rater agreement, reinforcing its role as a standardizing tool in aesthetic phlebology randomized controlled trials. These statistical findings should be weighed against the higher costs and complexity of LCS relative to CS in a purely cosmetic CEAP C1 population (see the Discussion section).

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Fonseca MM, Poltronieri LR, Argenta R, et al. Laser cryo-sclerotherapy versus conventional sclerotherapy for reticular veins and telangiectasias: A randomized controlled trial. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42637071. doi:10.1016/j.jvsv.2026.102605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。